Evidence map›Paper›PMID 41858057›Full record

ArticleJournal of medicinal chemistry2026

Reza Ebrahimighaei, Jon Lees, Robin A Corey, Boyi Xiao, Christopher Williams, Himali Y Godage, Vealmurugan Sekar, Hunaid Vohra, Deborah Shoemark, Andrew Newby and 1 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Reza EbrahimighaeiTranslational Health Sciences Bristol Medical School, University of Bristol, Bristol BS2 8HW, U.K.
Jon LeesTranslational Health Sciences Bristol Medical School, University of Bristol, Bristol BS2 8HW, U.K.
Robin A CoreySchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, BristolBS8 1TD, U.K.
Boyi XiaoSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, BristolBS8 1TD, U.K.
Christopher WilliamsSchool of Chemistry, Faculty of Science, University of Bristol, Cantock's Close, Bristol BS8 1TS, U.K.ORCID 0000-0001-5806-9842
Himali Y GodageSchool of Chemistry, Faculty of Science, University of Bristol, Cantock's Close, Bristol BS8 1TS, U.K.
Vealmurugan SekarTranslational Health Sciences Bristol Medical School, University of Bristol, Bristol BS2 8HW, U.K.
Hunaid VohraBristol Heart Institute, University Hospitals Bristol, NHS Foundation Trust, Bristol BS1 3NU, U.K.
Deborah ShoemarkSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, BristolBS8 1TD, U.K.
Andrew NewbyTranslational Health Sciences Bristol Medical School, University of Bristol, Bristol BS2 8HW, U.K.
Mark BondTranslational Health Sciences Bristol Medical School, University of Bristol, Bristol BS2 8HW, U.K.ORCID 0000-0003-2788-278X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear Transcription Factor-Y (NF-Y) is a transcription factor that binds CCAAT motifs to regulate gene expression, controlling cell proliferation, metabolism, and differentiation. NF-Y dysregulation contributes to diverse pathologies, including cancer, neurological disorders, cardiovascular disease, and tissue fibrosis. Using

Indexed as

CCAAT-Binding FactorDrug DiscoveryCell ProliferationComputer SimulationHumansMolecular Docking SimulationStructure-Activity RelationshipCCAAT-Binding Factor

Identifiers

PMID41858057
PMCPMC13071875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.